Baird Initiates Coverage On Calidi Biotherapeutics with Outperform Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Calidi Biotherapeutics (AMEX:CLDI) with an Outperform rating and a price target of $9.
October 09, 2023 | 9:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics has received an Outperform rating from Baird with a price target of $9.
The Outperform rating from Baird indicates a positive outlook for Calidi Biotherapeutics. The price target of $9 suggests that the analyst expects the stock to perform well in the short term. This could lead to an increase in investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100